Component
Serum liver enzyme elevation
Serum liver enzyme elevation. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Reversible asymptomatic liver-enzyme increases occurred in 11/28 patients receiving at least 30 mg/day; seven patients had serious adverse events of mixed attribution.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/molybdenum-research/28988934.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "6ca2c31c7a405be35fb18be79af77bbac1efc1dceb26a625f5a5cd35121cba7c", "start_char": 0, "end_char": 3591, "text_sha256": "6ca2c31c7a405be35fb18be79af77bbac1efc1dceb26a625f5a5cd35121cba7c"}
- experimental_model
- Open-label phase 2 trial in 28 adults with Wilson disease
- exposure
- 24 weeks of response-adjusted bis-choline tetrathiomolybdate
- limitations
- No blinded comparator. Pharmacological copper-binding drug, not nutritional molybdenum; endpoint corrects for drug-bound copper.
- nutrient_topic
- Molybdenum research collection; topical membership is not evidence of a direct dietary effect. · Molybdenum
- organism
- Homo sapiens
- plain_language
- The drug results include adverse effects as well as copper reduction.
- primary_references
- [mo-p28988934] Bis-choline tetrathiomolybdate in patients with Wilson's disease: an open-label, multicentre, phase 2 study. (2017). https://pubmed.ncbi.nlm.nih.gov/28988934/ DOI: 10.1016/s2468-1253(17)30293-5
- tissue_or_cell_type
- Plasma copper and clinical safety
Molybdenum: cofactor assembly, sulfur metabolism and nutrient interactions (2026-09-17) · lines 1652–1663
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Open-label phase 2 trial in 28 adults with Wilson disease · source_derived_draft · unverified_draft
### mo-ttm-human-safety Reversible asymptomatic liver-enzyme increases occurred in 11/28 patients receiving at least 30 mg/day; seven patients had serious adverse events of mixed attribution. Condition category: normal nutrient_topic: Molybdenum research collection; topical membership is not evidence of a direct dietary effect. plain_language: The drug results include adverse effects as well as copper reduction. organism: Homo sapiens tissue_or_cell_type: Plasma copper and clinical safety experimental_model: Open-label phase 2 trial in 28 adults with Wilson disease limitations: No blinded comparator. Pharmacological copper-binding drug, not nutritional molybdenum; endpoint corrects for drug-bound copper. exposure: 24 weeks of response-adjusted bis-choline tetrathiomolybdate evidence_span: {"source_cache": "artifacts/molybdenum-research/28988934.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "6ca2c31c7a405be35fb18be79af77bbac1efc1dceb26a625f5a5cd35121cba7c", "start_char": 0, "end_char": 3591, "text_sha256": "6ca2c31c7a405be35fb18be79af77bbac1efc1dceb26a625f5a5cd35121cba7c"} [mo-p28988934] Bis-choline tetrathiomolybdate in patients with Wilson's disease: an open-label, multicentre, phase 2 study. (2017). https://pubmed.ncbi.nlm.nih.gov/28988934/ DOI: 10.1016/s2468-1253(17)30293-5
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.